Spinal muscular atrophy (SMA) is traditionally molecularly diagnosed by multiplex ligation-dependent probe amplification or quantitative polymerase chain reaction (qPCR). SMA analyses are not routinely incorporated into gene panel analyses for individuals with suspected SMA or broader neuromuscular indications.
Aim:
We sought to determine whether a next-generation sequencing (NGS) approach that integrates SMA analyses into a multigene neuromuscular disorders panel could detect undiagnosed SMA.
Materials and Methods:
Sequence and copy number variants of the SMN1/SMN2 genes were simultaneously analyzed in samples from 5304 unselected individuals referred for testing using an NGS-based 122-gene neuromuscular panel. This diagnostic approach was validated using DNA from 68 individuals who had been previously diagnosed with SMA via quantitative PCR for SMN1/SMN2.
Results:
Homozygous loss of SMN1 was detected in 47 unselected individuals. Heterozygous loss of SMN1 was detected in 118 individuals; 8 had an indeterminate variant in “SMN1 or SMN2” that supported an SMA diagnosis but required additional disambiguation. Of the remaining SMA carriers, 44 had pathogenic variants in other genes. Concordance rates between NGS and qPCR were 100% and 93% for SMN1 and SMN2 copy numbers, respectively. Where there was disagreement, phenotypes were more consistent with the SMN2 results from NGS.
Conclusion:
Integrating NGS-based SMA testing into a multigene neuromuscular panel allows a single assay to diagnose SMA while comprehensively assessing the spectrum of variants that can occur in individuals with broad differential diagnoses or nonspecific/overlapping neuromuscular features.
Get full access to this article
View all access options for this article.
References
1.
AliasL, BernalS, Fuentes-PriorP, et al. (2009) Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet, 125:29-39.
2.
ArnoldWD, KassarD, KisselJT (2015) Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve, 51:157-167.
3.
BaiJL, QuYJ, CaoYY, et al. (2014) Subtle mutation detection of SMN1 gene in Chinese spinal muscular atrophy patients: implication of molecular diagnostic procedure for SMN1 gene mutations. Genet Test Mol Biomarkers, 18:546-551.
4.
BernalS, AliasL, BarcelMJ, et al. (2010) The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor. J Med Genet, 47:640-642.
5.
BernalS, Also-RalloE, Martinez-HernandezR, et al. (2011) Plastin 3 expression in discordant spinal muscular atrophy (SMA) siblings. Neuromuscul Disord, 21:413-419.
ChaeJH, VastaV, ChoA, et al. (2015) Utility of next generation sequencing in genetic diagnosis of early onset neuromuscular disorders. J Med Genet, 52:208-216.
8.
ChenX, Sanchis-JuanA, FrenchCE, et al. (2020) Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data. Genet Med, 22:945-953.
9.
ClermontO, BurletP, BenitP, et al. (2004) Molecular analysis of SMA patients without homozygous SMN1 deletions using a new strategy for identification of SMN1 subtle mutations. Hum Mutat, 24:417-427.
FengY, GeX, MengL, et al. (2017) The next generation of population-based spinal muscular atrophy carrier screening: comprehensive pan-ethnic SMN1 copy-number and sequence variant analysis by massively parallel sequencing. Genet Med, 19:936-944.
12.
FinkelRS, MercuriE, DarrasBT, et al. (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med, 377:1723-1732.
13.
GiannopoulouEZ, MartinT, WirthB, et al. (2015) Tongue fasciculations in an infant with spinal muscular atrophy type 1. Clin Case Rep, 3:832-834.
14.
HendricksonBC, DonohoeC, AkmaevVR, et al. (2009) Differences in SMN1 allele frequencies among ethnic groups within North America. J Med Genet, 46:641-644.
15.
HosokawaS, KuboY, ArakawaR, et al. (2020) Analysis of spinal muscular atrophy-like patients by targeted resequencing. Brain Dev, 42:148-156.
16.
KarakayaM, StorbeckM, StrathmannEA, et al. (2018) Targeted sequencing with expanded gene profile enables high diagnostic yield in non-5q-spinal muscular atrophies. Hum Mutat, 39:1284-1298.
17.
KariyaS, ParkGH, Maeno-HikichiY, et al. (2008) Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet, 17:2552-2569.
KurianAW, HareEE, MillsMA, et al. (2014) Clinical evaluation of a multi-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol, 32:2001-2009.
20.
LarsonJL, SilverAJ, ChanD, et al. (2015) Validation of a high resolution NGS method for detecting spinal muscular atrophy carriers among phase 3 participants in the 1000 Genomes Project. BMC Med Genet, 16:100.
21.
LawtonS, HickertonC, ArchibaldAD, et al. (2015) A mixed methods exploration of families' experiences of the diagnosis of childhood spinal muscular atrophy. Eur J Hum Genet, 23:575-580.
22.
LefebvreS, BurglenL, ReboulletS, et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell, 80:155-165.
23.
LinC, KalbSJ, YehWS (2015) Delay in diagnosis of spinal muscular atrophy: a systematic literature review. Pediatr Neurol, 53:293-300.
24.
LincolnSE, KobayashiY, AndersonMJ, et al. (2015) A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients. J Mol Diagn, 17:533-544.
25.
LiuB, LuY, WuB, et al. (2020) Survival motor neuron gene copy number analysis by exome sequencing: assisting spinal muscular atrophy diagnosis and carrier screening. J Mol Diagn, 22:619-628.
MailmanMD, HeinzJW, PappAC, et al. (2002) Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med, 4:20-26.
28.
MandelkerD, SchmidtRJ, AnkalaA, et al. (2016) Navigating highly homologous genes in a molecular diagnostic setting: a resource for clinical next-generation sequencing. Genet Med, 18:1282-1289.
29.
McGovernVL, Massoni-LaporteA, WangX, et al. (2015) Plastin 3 expression does not modify spinal muscular atrophy severity in the delta7 SMA mouse. PLoS One, 10:e0132364.
30.
MendellJR, Al-ZaidyS, ShellR, et al. (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 377:1713-1722.
31.
MonaniUR, PastoreMT, GavrilinaTO, et al. (2003) A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. J Cell Biol, 160:41-52.
32.
MorseR, ToddAG, ShawDJ, et al. (2011) Mutations in the survival motor neuron (SMN) protein alter the dynamic nature of nuclear bodies. Neuromolecular Med, 13:77-87.
33.
NykampK, AndersonM, PowersM, et al. (2017) Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. Genet Med, 19:1105-1117.
34.
O'GradyGL, LekM, LamandeSR, et al. (2016) Diagnosis and etiology of congenital muscular dystrophy: we are halfway there. Ann Neurol, 80:101-111.
35.
OhnoK, QuiramPA, MiloneM, et al. (1997) Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor epsilon subunit gene: identification and functional characterization of six new mutations. Hum Mol Genet, 6:753-766.
36.
OpreaGE, KroberS, McWhorterML, et al. (2008) Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science, 320:524-527.
37.
PaneM, LapentaL, AbiusiE, et al. (2017) Longitudinal assessment in discordant twins with SMA. Neuromuscul Disord, 27:890-893.
38.
ParsonsDW, McAndrewPE, IannacconeST, et al. (1998) Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am J Hum Genet, 63:1712-1723.
39.
ParsonsDW, McAndrewPE, MonaniUR, et al. (1996) An 11 base pair duplication in exon 6 of the SMN gene produces a type 1 spinal muscular atrophy (SMA) phenotype: further evidence for SMN as a primary SMA-determining gene. Hum Mol Genet, 5:1727-1732.
40.
PriorTW (2010) Perspectives and diagnostic considerations in spinal muscular atrophy. Genet Med, 12:145-152.
41.
PriorTW, KrainerAR, HuaY, et al. (2009) A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet, 85:408-413.
PriorTW, NaganN, SugarmanEA, et al. (2011) Technical standards and guidelines for spinal muscular atrophy testing. Genet Med, 13:686-694.
44.
QuYJ, BaiJL, CaoYY, et al. (2016) Mutation spectrum of the survival of motor neuron 1 and functional analysis of variants in Chinese spinal muscular atrophy. J Mol Diagn, 18:741-752.
45.
RobertsAM, WareJS, HermanDS, et al. (2015) Integrated allelic, transcriptional, and phenomic dissection of the cardiac effect of titin truncations in health and disease. Sci Transl Med, 7:270ra6.
46.
RussmanBS, MelchreitR, DrennanJC (1983) Spinal muscular atrophy: the natural course of disease. Muscle Nerve, 6:179-181.
47.
SkordisLA, DunckleyMG, BurglenL, et al. (2001) Characterisation of novel point mutations in the survival motor neuron gene SMN, in three patients with SMA. Hum Genet, 108:356-357.
48.
SunY, GrimmlerM, SchwarzerV, et al. (2005) Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy. Hum Mutat, 25:64-71.
49.
SwobodaKJ, PriorTW, ScottCB, et al. (2005) Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol, 57:704-712.
50.
TianX, LiangWC, FengY, et al. (2015) Expanding genotype/phenotype of neuromuscular diseases by comprehensive target capture/NGS. Neurol Genet, 1:e14.
51.
VezainM, Saugier-VeberP, GoinaE, et al. (2010) A rare SMN2 variant in a previously unrecognized composite splicing regulatory element induces exon 7 inclusion and reduced the clinical severity of spinal muscular atrophy. Hum Mutat, 31:E1110-E1125.
52.
WensSC, van GelderCM, KruijshaarME, et al. (2013) Phenotypical variation within 22 families with Pompe disease. Orphanet J Rare Dis, 8:182.
53.
WinderTL, TanCA, KlemmS, et al. (2020) Clinical utility of multigene analysis in over 25,000 patients with neuromuscular disorders. Neurol Genet, 6:e412.
54.
WirthB (2000) An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat, 15:228-237.
55.
WuX, WangSH, SunJ, et al. (2017) A -44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy. Hum Mol Genet, 26:2768-2780.
56.
YenerIH, TopalogluH, Erdem-Ozdamar, et al. (2017) Transcript levels of plastin 3 and neuritin 1 modifier genes in spinal muscular atrophy siblings. Pediatr Int, 59:53-56.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
